» Articles » PMID: 35331296

Targeting Extracellular Matrix Stiffness and Mechanotransducers to Improve Cancer Therapy

Overview
Journal J Hematol Oncol
Publisher Biomed Central
Specialties Hematology
Oncology
Date 2022 Mar 25
PMID 35331296
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer microenvironment is critical for tumorigenesis and cancer progression. The extracellular matrix (ECM) interacts with tumor and stromal cells to promote cancer cells proliferation, migration, invasion, angiogenesis and immune evasion. Both ECM itself and ECM stiffening-induced mechanical stimuli may activate cell membrane receptors and mechanosensors such as integrin, Piezo1 and TRPV4, thereby modulating the malignant phenotype of tumor and stromal cells. A better understanding of how ECM stiffness regulates tumor progression will contribute to the development of new therapeutics. The rapidly expanding evidence in this research area suggests that the regulators and effectors of ECM stiffness represent potential therapeutic targets for cancer. This review summarizes recent work on the regulation of ECM stiffness in cancer, the effects of ECM stiffness on tumor progression, cancer immunity and drug resistance. We also discuss the potential targets that may be druggable to intervene ECM stiffness and tumor progression. Based on these advances, future efforts can be made to develop more effective and safe drugs to interrupt ECM stiffness-induced oncogenic signaling, cancer progression and drug resistance.

Citing Articles

Piezo1-related physiological and pathological processes in glioblastoma.

Fu W, Hou X, Ding L, Wei J, Hou W Front Cell Dev Biol. 2025; 13:1536320.

PMID: 40061015 PMC: 11885286. DOI: 10.3389/fcell.2025.1536320.


Redox regulation: mechanisms, biology and therapeutic targets in diseases.

Li B, Ming H, Qin S, Nice E, Dong J, Du Z Signal Transduct Target Ther. 2025; 10(1):72.

PMID: 40050273 PMC: 11885647. DOI: 10.1038/s41392-024-02095-6.


A mathematical model to predict network growth in as a function of extracellular matrix viscosity, measured by a novel viscometer.

Rosina P, Grube M J R Soc Interface. 2025; 22(224):20240720.

PMID: 40037543 PMC: 11879620. DOI: 10.1098/rsif.2024.0720.


Identification of an extracellular matrix signature for predicting prognosis and sensitivity to therapy of patients with gastric cancer.

Xu N, Zhang T, Sun W, Ye C, Zhou H Sci Rep. 2025; 15(1):7464.

PMID: 40032943 PMC: 11876314. DOI: 10.1038/s41598-025-88376-8.


A glucose-enriched lung pre-metastatic niche triggered by matrix stiffness-tuned exosomal miRNAs in hepatocellular carcinoma.

Zhao Y, Yu H, Li J, Qian J, Li M, Zhang X Nat Commun. 2025; 16(1):1736.

PMID: 39966385 PMC: 11836368. DOI: 10.1038/s41467-025-56878-8.


References
1.
Chen Y, Guo H, Terajima M, Banerjee P, Liu X, Yu J . Lysyl Hydroxylase 2 Is Secreted by Tumor Cells and Can Modify Collagen in the Extracellular Space. J Biol Chem. 2016; 291(50):25799-25808. PMC: 5207055. DOI: 10.1074/jbc.M116.759803. View

2.
Zhang Y, Yin Y, Liu S, Yang L, Sun C, An R . FK506 binding protein 10: a key actor of collagen crosslinking in clear cell renal cell carcinoma. Aging (Albany NY). 2021; 13(15):19475-19485. PMC: 8386577. DOI: 10.18632/aging.203359. View

3.
Joyce M, Lu C, James E, Hegab R, Allen S, Suggs L . Phenotypic Basis for Matrix Stiffness-Dependent Chemoresistance of Breast Cancer Cells to Doxorubicin. Front Oncol. 2018; 8:337. PMC: 6134055. DOI: 10.3389/fonc.2018.00337. View

4.
Nicolas-Boluda A, Vaquero J, Vimeux L, Guilbert T, Barrin S, Kantari-Mimoun C . Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. Elife. 2021; 10. PMC: 8203293. DOI: 10.7554/eLife.58688. View

5.
Hua H, Li M, Luo T, Yin Y, Jiang Y . Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci. 2011; 68(23):3853-68. PMC: 11114831. DOI: 10.1007/s00018-011-0763-x. View